ADT1125-Cemiplimab Biosimilar-Anti-PDCD1/PD1/CD279 mAb-Research Grade

Catalog Number

ADT1125

Product Name

ADT1125-Cemiplimab Biosimilar-Anti-PDCD1/PD1/CD279 mAb-Research Grade

Alias

REGN-2810,  SAR-439684,  cemiplimab-rwlc

Clonity

Monoclonal

Alternate Names

anti-mouse pd-1 antibody,  anti-pd-1 antibody,  anti pd-1 antibody,  recombinant pd-1,  pd-1 antibody,  anti-pd-1 monoclonal antibody,  pd-1 antibodies,  pd-1 recombinant antibody,  pd-1 blocking antibody, CD279 recombinant antibody,  CD279 blocking antibody

Host

CHO Cells

Species

Human

Target

PDCD1/PD-1/CD279

Gene ID

5133

Isotype

IgG4 Kappa

Size

1mg, 5mg

Research Area

Cancer

CAS Number

1801342-60-8

Product Description

Cemiplimab,  sold under the brand name Libtayo,  is a monoclonal antibody medication for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1),  blocking the PD-1/PD-L1 pathway.

Mechanism of Action

Binding of the programmed death receptor (PD) ligands PD-L1 and PD-L2,  to the PD-1 receptor,  which is found on T cells,  Inhibitionits T-cell proliferation and cytokine production. The upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway may contribute to the Inhibitionition of active T-cell immune surveillance of tumors. Cemiplimab is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2 ligands,  causing PD-1 pathway-mediated Inhibitionition of the immune response,  including the anti-tumor immune response. In mouse tumor models,  blocking PD-1 activity resulted in decreased rates of tumor growth.

Application

Elisa,  WB

Purity

>95% as determined by SDS-PAGE

Concentration

batch dependent

Buffer

Supplied in PBS,  PH7.5

Storage

Store at -20 °C for 12 months. Store at -80 °C for long term storage.

Shipping Condition

Shipped on ice packs.

Note

This product is for research use only.

Reference